J ETHNOPHARMACOL 润色咨询

JOURNAL OF ETHNOPHARMACOLOGY

出版年份:1979 年文章数:10328 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:8.4% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-12-07 ms9000001673281029 来自云南省

    偏重的研究方向:靶点;单体
    经验分享:with editor2周多了,要不要催?最近这么慢吗

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-12-12 147c023fm79(暂无昵称) 来自北京

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:生信分析+人样本验证+药效
    经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。
    1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;
    2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;
    3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。
    祝大家都好运!

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-07-05 卡球球 zhao 来自广东省

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:中药复方机制
    经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!

    20

    展开20条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-10-14 ms4000001105476217 来自北京

    请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-09-17 ms6000000645412256

    偏重的研究方向:药理学;天然药物;药理
    经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-09-06 ms3000000237799877 来自四川省

    一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗

    7

    展开7条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2024-01-15 ms9000000742155435 来自上海

    投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-07-08 ms1000000125278461 来自重庆

    投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-11-25 ms3000001423208311 来自浙江省

    请问online之后多久能拿到检索证明啊?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2173434, encodeId=981b21e3434ac, content=偏重的研究方向:靶点;单体<br>经验分享:with editor2周多了,要不要催?最近这么慢吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1e25413810, createdName=ms9000001673281029, createdTime=Thu Dec 07 08:50:50 CST 2023, time=2023-12-07, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2174485, encodeId=ba4321e448530, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生信分析+人样本验证+药效<br>经验分享:感谢论坛中的大神为我避开了一些坑,在此分享传递爱心。具体时间点为下 2023.11.1 提交 11.21 两位审稿人修改意见 12.6提交修改稿 12.11接收。<br>1.中药复方的质控很重要,需要根据国家药典定量检测复方中每种组成药物的成分,如果团队之前发表的文章做过,建议在cover letter强调一下,正文也简单写几句,标注文献;<br>2.投稿须知写明需要多剂量,如果前期筛选过优势剂量,也建议在cover letter强调一下,正文也有体现;<br>3.审稿建议还需要有毒理实验和药代动力学,如果没做,要阐述清楚理由。<br>祝大家都好运!<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da5c5241456, createdName=147c023fm79(暂无昵称), createdTime=Tue Dec 12 14:40:51 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2146523, encodeId=4e192146523e2, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:中药复方机制<br>经验分享:4.1第一次投稿,被编辑部退回,理由如下:1. 杂志一般不接受单剂量研究,如果有前期剂量筛选的话要补充依据;2. 补充受试药物的传统应用依据;3. 补充动物伦理证明。起初以为杂志不接受单剂量,转战phytomedicine (编辑建议转投)和frontiers in pharmacology(要求进行语言润色,主动撤稿)。后面经邮件咨询编辑部后,于4.30再次投稿,5.8送外审,6.27审稿意见返回,两个审稿人9个问题,编辑给了7天修改,7.3修回(9个问题回复了9页纸),7.5accept。总体感觉相对不难,但是要注意细节,例如:摘要个格式要严格按照要求来;要有动物伦理证明;如果是单剂量研究要说明理由(正文材料方法中、cover letter都要讲清楚,不然会被退稿);中药/复方要有传统应用的依据(这里要引用相应的文献支撑)。另外,对于审稿人的刁难,舔就完事了哈哈哈!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b5e25499089, createdName=卡球球 zhao, createdTime=Wed Jul 05 21:59:09 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2162744, encodeId=86b12162e449f, content=请问各位大神,An annotated Table of Contents (Index) must be provided for reviews as required for the journal.是什么意思,要提供什么材料吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e545685662, createdName=ms4000001105476217, createdTime=Sat Oct 14 11:29:12 CST 2023, time=2023-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2158170, encodeId=f0ab21581e069, content=偏重的研究方向:药理学;天然药物;药理<br>经验分享:家人们,想问一下投的综述一般要多久送审呀,投了有几天了还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13a48217662, createdName=ms6000000645412256, createdTime=Sun Sep 17 18:24:08 CST 2023, time=2023-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156372, encodeId=dce321563e2be, content=一审:第一个审稿人提了对内容提了7个问题,第二个审稿人给了接收,请问小修回去还需要送外审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3008394011, createdName=ms3000000237799877, createdTime=Wed Sep 06 14:15:05 CST 2023, time=2023-09-06, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2181831, encodeId=490a2181831d7, content=投稿要求“Please download a paper from the journal website and use it as an example to correct the format of your paper.”请问文章格式是什么啊,怎么改啊,急求, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cff78834013, createdName=ms9000000742155435, createdTime=Mon Jan 15 17:47:34 CST 2024, time=2024-01-15, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2147022, encodeId=0f71214e02205, content=投稿一周了还是submited to journal, 真的很希望送审。我是筛药的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7aa96399896, createdName=ms1000000125278461, createdTime=Sat Jul 08 22:12:51 CST 2023, time=2023-07-08, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2170852, encodeId=be0d21e085259, content=请问online之后多久能拿到检索证明啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6d5433134, createdName=ms3000001423208311, createdTime=Sat Nov 25 08:16:05 CST 2023, time=2023-11-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2176059, encodeId=c7ae21e6059ed, content=5天了,还是Submitted to Journal,要不要催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aaeb1710704, createdName=Spiriting, createdTime=Wed Dec 20 10:30:53 CST 2023, time=2023-12-20, status=1, ipAttribution=山东省)]
    2023-12-20 Spiriting 来自山东省

    5天了,还是Submitted to Journal,要不要催一下

    0

共500条页码: 2/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分